Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomised controlled trial
<p>Chronic kidney disease (CKD) is associated with substantial risk of progression to end stage renal disease and vascular events. The non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardio-renal protection for people with CKD and diabetes, but there is uncertaint...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2024
|